Drug Profile
LV 305
Alternative Names: Cancer vaccine DCVex NY-ESO-1 - Immune Design; DCVex™/NY-ESO-1 cancer vaccine - Immune Design; ID-LV305; LV 305Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Immune Design
- Class Cancer vaccines; RNA vaccines
- Mechanism of Action Dendritic cell stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Solid tumours
- No development reported Breast cancer; Liposarcoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Synovial sarcoma
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Liposarcoma(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intradermal, Injection)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Synovial-sarcoma(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intradermal, Injection)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease) in USA (Intradermal, Injection)